NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER
30 September 2019 - 4:30PM
NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE
OFFICER
PRESS RELEASE ·
PRESS RELEASE ·
PRESS RELEASE
NEOVACS ANNOUNCES APPOINTMENT
OFVINCENT SERRA AS CHIEF EXECUTIVE
OFFICER
Paris & Boston, September 30, 2019 –
08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a
leader in active immunotherapies for the treatment of auto-immune
diseases, has today announced, the appointment of Vincent Serra,
PhD, as the new Chief Executive Officer, with immediate effect, to
succeed Miguel Sieler who has resigned as CEO and as a board
director.
Jean-Jacques Bertrand, President of the Neovacs
Board of Directors declared: “On behalf of the Board of Directors I
am delighted to welcome Vincent Serra as the CEO. Vincent has the
leadership qualities and operational experience needed to carry our
innovative kinoid technology forward to the market and to
contribute to the overall success of the company.”
Vincent Serra, 50 years, doctor of immunology,
has more than 20 years of experience leading biotechnology
operations notably in the immunology field. He is the author of
several patents, and scientific, peer reviewed articles and
publications in the area of vaccinations. Prior to joining Neovacs
as Chief Scientific Officer (CSO) at the beginning of the year, he
was head of external innovation at Pierre Fabre and SVP of the
Pierre Fabre innovation fund. Vincent Serra has also exercised the
roles of CSO, CEO and cofounder of a number of biotech companies.
In addition, he has put in place numerous in and out licensing
agreements and developed different products up to clinical
development as well as being involved in the IPO of Abivax.
« I am delighted to take on this
role to head up the Neovacs team, committed to developing our
kinoid technology. With the support of a worldwide network of
renown experts, we are preparing the different clinical and
preclinical steps for therapeutic vaccines” said Vincent Serra,
adding: “ I will drive Neovacs’ mission to bring efficient,
innovative treatments to the millions of people suffering from auto
immune diseases with no real therapeutic solution today.”
Neovacs will announce its half-year results and
update on its activities on October 2, 2019 as previously
announced.
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is
today a leading biotechnology company focused on an active
immunotherapy technology platform (Kinoids) with applications in
autoimmune and/or inflammatory diseases. On the basis of the
company’s proprietary technology for inducing a polyclonal immune
response (covered by four patent families that potentially run
until 2032) Neovacs is focusing its clinical development efforts on
IFNα-Kinoid, an immunotherapy being developed for the indication of
lupus, dermatomyositis and also in preclinical trial for Type 1
diabetes. Neovacs is also conducting preclinical development works
on other therapeutic vaccines in the fields of auto-immune
diseases, oncology and allergies. The goal of the Kinoid approach
is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
www.neovacs.fr
Contacts
NEOVACS – Corporate Communication
& Investor RelationsCharlène
Masson+33 1 53 10 93 00cmasson@neovacs.com
NEWCAP- Media
Annie-Florence Loyer +33 1 44 71 00 12 / + 33
6 88 20 35 59afloyer@newcap.fr Léa Jacquin +33 1
44 71 20 41 / +33 6 58 14 84 66ljacquin@newcap.fr
ORPHEON FINANCE – Financial
Communication and Investor RelationsJames
Palmer +33 7 60 92 77 74j.palmer@orpheonfinance.com
Neovacs (EU:ALNEV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Nov 2023 to Nov 2024
